Destroying Cancer at the Speed of Light®

Clinical Study Underway (63 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026

Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.W

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Bullboard (TSXV:TLT)

View:

Comment by Eoganachton May 19, 2024 2:03pm

RE:RE:Dr. Kamat Speaks with ImmunityBio's Dr. Soon-Shiong

I would also note that that 58% CR at 12 months was not the CR percentage of the 77 patient trial population. It was the percentage of the 48 out of 77 patients (62% CR at any time) who were still CR ...more

146

Discussion

Comment by Eoganachton May 19, 2024 12:06pm

RE:RE:Dr. Kamat Speaks with ImmunityBio's Dr. Soon-Shiong

Good post DJDawg. We clearly have decisively better efficacy than Anktiva and the limited number of Ruvidar treatments required should end up being a big advantage.

Discussion

Comment by DJDawgon May 19, 2024 9:41am

RE:Dr. Kamat Speaks with ImmunityBio's Dr. Soon-Shiong

A few thoughts about this very interesting interview. Dr. Soon-Shiong is very excited by how the anktiva got a 58% rate at 12m vs the IBCG recommendation of 30% or greater. I looked up the IBCG ...more

143

Discussion

Comment by chry200030on May 19, 2024 9:22am

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Keep patient, maybe we are at last step to the final victory

So, please tell us........... why are you here ???????

Discussion

Comment by Infinityon May 19, 2024 6:44am

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Keep patient, maybe we are at last step to the final victory

This stock has been underperforming for years for no apparent reason. We have stellar clinical test results as reported by the management. The company has been struggling to raise ...more

119

Discussion

Comment by stocksnbonds458on May 18, 2024 9:45pm

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Keep patient, maybe we are at last step to the final victory

For goodness sake people, why waste your time creating these complicated and quite frankly incorrect theories about why it has taken so long to reply to the FDA's Pre-BTD questions? Why not just ...more

166

Discussion

Comment by Oilminerdeluxeon May 18, 2024 12:59pm

RE:RE:RE:RE:Dr. Kamat Speaks with ImmunityBio's Dr. Soon-Shiong

Ah, yes, that one is lurking around the corner. Thanks, skys. Well, that should be at least a little bit informative.

Discussion

Comment by skys1on May 18, 2024 12:04pm

RE:RE:RE:Dr. Kamat Speaks with ImmunityBio's Dr. Soon-Shiong

Oilminer - The AGM is next month.

Discussion

Comment by Oilminerdeluxeon May 18, 2024 10:33am

RE:RE:Dr. Kamat Speaks with ImmunityBio's Dr. Soon-Shiong

Time for some updates, imho. We are a bit starved.

Discussion

Comment by O12009on May 18, 2024 10:20am

RE:Dr. Kamat Speaks with ImmunityBio's Dr. Soon-Shiong

Thanks for the post, very informative. In the part 2 Dr Patrick says they can continue to treat up to 37 months. So is this treatment an on going treatment like BCG and what happens if it is stopped ...more

110

Discussion

Post by Alamir1111on May 18, 2024 8:23am

Lung

https://www.fiercepharma.com/pharma/fda-nod-amgens-watershed-lung-cancer-drug-could-make-it-rain?itm_source=parsely-api

Comment by Alamir1111on May 17, 2024 7:21pm

RE:RE:Dr. Kamat Speaks with ImmunityBio's Dr. Soon-Shiong

Have a feeling Merck will be doing some rimming at Fda regarding serums bcg

Discussion

Comment by Alamir1111on May 17, 2024 5:57pm

RE:Dr. Kamat Speaks with ImmunityBio's Dr. Soon-Shiong

So that's the good news because it's an immunological stimulant. What I'm really excited about is the potential that the Serum Institute's next generation recombinant BCG is even more ...more

131

Discussion

Comment by riverrrowon May 17, 2024 5:43pm

RE:Usual share price and volume shifting

A friend did a cross once accidentally within the same brokerage firm and their brokerage firm was all over them threatening to suspend their account. I imagine a cross involving two separate ...more

151

Discussion

Post by Eoganachton May 17, 2024 5:37pm

Dr. Kamat Speaks with ImmunityBio's Dr. Soon-Shiong

In this 3 part interview, posted yesterday, Dr. Kamat speaks with Dr. Soon-Shiong about ImmunityBio's newly FDA approved treatment for BCG-unresponsive NMIBC with CIS, with or without ...more

279

Discussion

The Market Update

< Previous bulletin

Next bulletin >

A daily snapshot of everything
from market open to close.

Connect with V.TLT

INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

FACT SHEET

The Watchlist

< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

Clinical Study with 63 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
Best-in-class treatment for NMIBC (according to interim clinical data)
NMIBC (Non-Muscle-Invasive Bladder Cancer)

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250

Become a member today, It's free!

Sign In

Send my password

Become a member today, It's free!

Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.W

Join the community and start posting on the bullboards today. It's free.

Create a portfolio watchlist today. It's free.

Bullboard (TSXV:TLT)

Connect with V.TLT

Investor Presentation

FACT SHEET

The Watchlist

Investment Opportunity

Facebook

Contact Us